SCHEMBL4535226

SCHEMBL4535226

CCc1ccc(-c2cccc(-c3cnc(N)o3)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
MEN1 O00255 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TP53 P04637 1/20 0.37
MITF O75030 1/20 0.37
FLT1 P17948 3/20 0.37
FLT4 P35916 3/20 0.37
KDR P35968 3/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4528767 0.83 RAB9A (0.47) MEN1RAB9AKMT2AKDM4ENPC1
SCHEMBL4534098 0.81 RAB9A (0.44) MEN1RAB9AKMT2AKDM4ENPC1
SCHEMBL4534870 0.79 KDR (0.47) CYP3A4MEN1RAB9AKMT2AKDM4E
SCHEMBL4530786 0.78 RAB9A (0.41) MEN1RAB9AKMT2AKDM4ENPC1
SCHEMBL4539660 0.76 HSD17B1 (0.55) CYP3A4MEN1KMT2AALDH1A1MAPT
SCHEMBL11326904 0.76 BCL2 (0.53) CYP3A4MEN1KMT2ATP53MAPKAPK2
SCHEMBL4532640 0.75 RXRA (0.40) MEN1RAB9AKMT2AKDM4ENPC1
SCHEMBL14650182 0.75 MAP4K4 (0.54) MEN1RAB9AKMT2AKDM4ENPC1
SCHEMBL4537136 0.75 MEN1 (0.56) CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL4539780 0.73 MAP4K4 (0.49) RAB9AKMT2ANPC1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
EP-1648876-A1 5-HT SB 2B /SB RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2006-04-26 EP disclosed
WO-2005012263-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018150-A1 5-Ht2b Receptor Antagonists HTR2B, HTR1B, HTR3B CYP17A1 2276/4885CYP3A4 604/4885CYP19A1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.